# Phase I/II FIH Study of 9MW2921 in Patients With Advanced Solid Tumors

> **NCT05990452** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Mabwell (Shanghai) Bioscience Co., Ltd.** · enrollment: 261 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** 9MW2921

## Key facts

- **NCT ID:** NCT05990452
- **Lead sponsor:** Mabwell (Shanghai) Bioscience Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-08-28
- **Primary completion:** 2026-09-01
- **Final completion:** 2026-12-30
- **Target enrollment:** 261 (ESTIMATED)
- **Last updated:** 2024-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05990452

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05990452, "Phase I/II FIH Study of 9MW2921 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT05990452. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*